High Tumor Mutational Burden May Predict Improved Response to Immunotherapy in Head and Neck Cancer Patients

被引：0
|
作者：
Stewart, M. [1 ]
Reddy, C. A. [2 ]
Woody, N. M. [2 ]
Sussman, T. [3 ]
Yilmaz, E. [1 ]
Geiger, J. L. [1 ]
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA
[2] Cleveland Clin, Taussig Canc Inst, Dept Radiat Oncol, Cleveland, OH 44106 USA
[3] Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol, Cleveland, OH 44106 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
162
引用
收藏
页码：E43 / E43
页数：1
相关论文
共 50 条
  • [41] New biological markers may accurately predict prognosis in head and neck cancer patients
    不详
    ONCOLOGY-NEW YORK, 1998, 12 (10): : 1537 - 1537
  • [42] Serial tumor radiomic features predict response of head and neck cancer treated with Radiotherapy
    Elhalawani, H. E.
    Mohamed, A. S. R.
    Volpe, S.
    Yang, P.
    Campbell, S.
    Granberry, R.
    Ger, R.
    Fave, X.
    Zhang, L.
    Marai, G. E.
    Vock, D.
    Canahuate, G. M.
    Mackin, D.
    Court, L.
    Gunn, G. B.
    Rao, A.
    Fuller, C. D.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : E551 - E551
  • [43] High Tumor Mutational Burden Identifies Specific Subsets of Pancreatic Cancer Patients with Prolonged Survival and Improved Anti-tumor Immunity
    Karamitopoulou-Diamantis, Eva
    Andreou, Andreas
    Wenning, Anna-Silvia
    Gloor, Beat
    Perren, Aurel
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1223 - 1224
  • [44] High Tumor Mutational Burden Identifies Specific Subsets of Pancreatic Cancer Patients with Prolonged Survival and Improved Anti-tumor Immunity
    Karamitopoulou-Diamantis, Eva
    Andreou, Andreas
    Wenning, Anna-Silvia
    Gloor, Beat
    Perren, Aurel
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1223 - 1224
  • [45] The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy
    Waqar, Saiama N.
    Govindan, Ramaswamy
    JAMA ONCOLOGY, 2020, 6 (05) : 674 - 675
  • [46] Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis
    Wu, Rui-Yan
    Wang, Bi-Cheng
    Wang, Kun
    Xia, Fan
    Zhang, Zhi-Yuan
    Wan, Jue-Feng
    Zhang, Zhen
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [47] High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
    Riviere, Paul
    Goodman, Aaron M.
    Okamura, Ryosuke
    Barkauskas, Donald A.
    Whitchurch, Theresa J.
    Lee, Suzanna
    Khalid, Noor
    Collier, Rachel
    Mareboina, Manvita
    Frampton, Garrett M.
    Fabrizio, David
    Sharabi, Andrew B.
    Kato, Shumei
    Kurzrock, Razelle
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) : 2139 - 2145
  • [48] Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer
    Barroso-Sousa, Romualdo
    Jain, Esha
    Kim, Dewey
    Partridge, Ann H.
    Cohen, Ofir
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Residual concentrations of cetuximab predict clinical response in head and neck cancer patients
    Ciccolini, Joseph
    Becher, Francois
    Imbs, Diane-Charlotte
    Fournel, Claire
    Duffaud, Florence
    Lacarelle, Bruno
    Salas, Sebastien
    CANCER RESEARCH, 2017, 77
  • [50] Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy (vol 75, pg 129, 2020)
    Crow, J.
    Samuel, G.
    Godwin, A. K.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2020,
12345